Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 3/20 | 0.42 |
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | FABP4 | P15090 | 1/20 | 0.40 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.40 |
| ▸ | EGLN3 | Q9H6Z9 | 2/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.39 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PTGIR | P43119 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5521617 | 0.94 | TBXAS1 (0.49) | TBXAS1FDPSHTTTHRBFABP4 | |
| SCHEMBL9845290 | 0.93 | TBXAS1 (0.51) | TBXAS1KMT2AFABP4LMNAPTGIR | |
| SCHEMBL9845261 | 0.93 | TBXAS1 (0.51) | TBXAS1KMT2AFABP4LMNAPTGIR | |
| SCHEMBL5514714 | 0.93 | TBXAS1 (0.51) | TBXAS1KMT2AFABP4LMNAPTGIR | |
| Water SCHEMBL9845268 | 0.91 | TBXAS1 (0.50) | TBXAS1KMT2AFABP4LMNAPTGIR | |
| SCHEMBL4663218 | 0.88 | EGLN3 (0.50) | FDPSHTTTHRBKMT2AEGLN3 | |
| Hydrochloric Acid SCHEMBL17337686 | 0.86 | EGLN3 (0.48) | FDPSHTTTHRBKMT2AEGLN3 | |
| SCHEMBL4797270 | 0.85 | LMNA (0.41) | FDPSHTTTHRBKMT2ALMNA | |
| SCHEMBL21996470 | 0.83 | THRB (0.43) | FDPSTHRBKMT2ALMNAPOLB | |
| SCHEMBL6446995 | 0.79 | LMNA (0.40) | FDPSHTTTHRBKMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100055116-A1 | Methods and Compositions for Targeting c-Rel | CORNELL RESEARCH FOUNDATION, INC. | 2010-03-04 | — | — | US | claimed |
| CN-101460634-A | Methods and compositions for targeting C-REL | CORNELL RES FOUNDATION INC (US) | 2009-06-17 | — | — | CN | claimed |
| EP-2010225-A2 | METHODS AND COMPOSITIONS FOR TARGETING C-REL | Cornell Research Foundation, Inc. (US) | 2009-01-07 | — | — | EP | claimed |
| WO-2007120842-A2 | METHODS AND COMPOSITIONS FOR TARGETING C-REL | CORNELL RESEARCH FOUNDATION, INC. (US) | 2007-10-25 | — | — | WO | claimed |
| EP-4029868-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-05-20 | — | — | EP | disclosed |
| CN-117304130-A | MCL-1 inhibitors | 吉利德科学公司 | 2023-12-29 | — | — | CN | disclosed |
| US-20230312490-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| CN-112118845-B | MCL-1 inhibitors | 吉利德科学公司 | 2023-06-13 | — | — | CN | disclosed |
| US-11643400-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20220340535-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2022-10-27 | — | — | US | disclosed |
| EP-4029868-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2022-07-20 | — | — | EP | disclosed |
| EP-3793565-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2022-01-05 | — | — | EP | disclosed |
| WO-2006134486-A2 | ALPHA-(ARYL-OR HETEROARYL-METHYL)-BETA PIPERIDINO PROPANAMIDE COMPOUNDS AS ORL1-RECEPTOR ANTAGONISTS | PFIZER JAPAN INC. (JP) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006134485-A1 | ALPHA-(ARYL-OR HETEROARYL-METHYL)-BETA-PIPERIDINOPROPANOIC ACID COMPOUNDS AS ORL1-RECEPTOR ANTAGONISTS | PFIZER JAPAN INC. (JP) | 2006-12-21 | — | — | WO | disclosed |
| EP-1732893-A2 | ALPHA ARYL OR HETEROARYL METHYL BETA PIPERIDINO PROPANAMIDE COMPOUNDS AS ORL1-RECEPTOR ANTAGONIST | Pfizer Japan, Inc. (JP) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005092858-A2 | ALPHA ARYL OR HETEROARYL METHYL BETA PIPERIDINO PROPANAMIDE COMPOUNDS AS ORL1-RECEPTOR ANTAGONIST | PFIZER JAPAN INC. (JP) | 2005-10-06 | — | — | WO | disclosed |
| US-20050148702-A1 | Composition and its use for imparting water repellency to leather or furskins, textiles and other fibrous materials | TFL LEDERTECHNIK GMBH (DE) | 2005-07-07 | — | — | US | disclosed |
| EP-1470258-A1 | COMPOSITION AND ITS USE FOR IMPARTING WATER REPELLENCY TO LEATHER OR FURSKINS, TEXTILES AND OTHER FIBROUS MATERIALS | TFL Ledertechnik GmbH (DE) | 2004-10-27 | — | — | EP | disclosed |
| WO-2003064707-A1 | COMPOSITIONS AND ITS USE FOR IMPARTING WATER REPELLENCY TO LEATHER OR FURSKINS, TEXTILES AND OTHER FIBROUS MATERIALS | TFL LEDERTECHNIK GMBH (DE) | 2003-08-07 | — | — | WO | disclosed |
| CN-1069271-A | Preparation [1] chromene is the method for [4,3-c] pyrazole compound also | BOOTS CO PLC (GB) | 1993-02-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312490-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | TBXAS1 3051/4885FDPS 3576/4885HTT 2323/4885 |
| US-11643400-B2 | MCL-1 inhibitors | MCL1, BCL2L1, BCL2 | TBXAS1 3051/4885FDPS 3576/4885HTT 2323/4885 |
| US-20100055116-A1 | Methods and Compositions for Targeting c-Rel | REL, NFATC1, MYCBP | TBXAS1 3831/4885FDPS 4348/4885HTT 2949/4885 |
| US-20220340535-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | TBXAS1 3051/4885FDPS 3576/4885HTT 2323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.